HCM

HUTCHMED China (HCM)

HUTCHMED China Limited

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:HCM

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/09/24	19:09	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2024/09/24	16:00	GlobeNewswire Inc.	HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda	NASDAQ:HCM	HUTCHMED China Limited
2024/09/18	00:22	GlobeNewswire Inc.	International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024	NASDAQ:HCM	HUTCHMED China Limited
2024/09/09	09:00	GlobeNewswire Inc.	HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer	NASDAQ:HCM	HUTCHMED China Limited
2024/08/30	19:13	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2024/08/30	13:30	GlobeNewswire Inc.	HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China	NASDAQ:HCM	HUTCHMED China Limited
2024/08/22	19:10	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2024/08/21	19:07	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2024/08/21	17:30	GlobeNewswire Inc.	HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia	NASDAQ:HCM	HUTCHMED China Limited
2024/07/31	20:13	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2024/07/31	20:00	GlobeNewswire Inc.	HUTCHMED Reports 2024 Interim Results and Provides Business Updates	NASDAQ:HCM	HUTCHMED China Limited
2024/07/04	09:00	GlobeNewswire Inc.	HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status	NASDAQ:HCM	HUTCHMED China Limited
2024/06/26	17:30	GlobeNewswire Inc.	HUTCHMED to Announce 2024 Half-Year Financial Results	NASDAQ:HCM	HUTCHMED China Limited
2024/06/24	18:30	GlobeNewswire Inc.	Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024	NASDAQ:HCM	HUTCHMED China Limited
2024/06/22	05:00	GlobeNewswire Inc.	HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda	NASDAQ:HCM	HUTCHMED China Limited
2024/06/17	09:00	GlobeNewswire Inc.	HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology	NASDAQ:HCM	HUTCHMED China Limited
2024/06/07	19:25	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2024/06/07	09:00	GlobeNewswire Inc.	HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China	NASDAQ:HCM	HUTCHMED China Limited
2024/06/03	19:13	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2024/06/03	09:00	GlobeNewswire Inc.	HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine	NASDAQ:HCM	HUTCHMED China Limited
2024/05/31	19:12	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2024/05/24	19:06	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2024/05/24	09:00	GlobeNewswire Inc.	HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting	NASDAQ:HCM	HUTCHMED China Limited
2024/05/17	23:02	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2024/05/17	23:00	GlobeNewswire Inc.	HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees	NASDAQ:HCM	HUTCHMED China Limited
2024/05/17	09:00	GlobeNewswire Inc.	HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress	NASDAQ:HCM	HUTCHMED China Limited
2024/05/14	09:00	GlobeNewswire Inc.	HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China	NASDAQ:HCM	HUTCHMED China Limited
2024/05/14	09:00	GlobeNewswire Inc.	HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui	NASDAQ:HCM	HUTCHMED China Limited
2024/05/08	17:30	GlobeNewswire Inc.	HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee	NASDAQ:HCM	HUTCHMED China Limited
2024/04/26	21:30	GlobeNewswire Inc.	HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda	NASDAQ:HCM	HUTCHMED China Limited